Loading...
•
Dec 31, 2024
Heron Therapeutics Q4 2024 Earnings Report
Reported positive net income and revenue growth, driven by ZYNRELEF and strategic partnerships.
Key Takeaways
Heron Therapeutics reported a successful Q4 2024, achieving GAAP net income of $3.6 million. Full-year 2024 net revenue reached $144.2 million, a 14% increase year-over-year. The company is focused on expanding ZYNRELEF's market reach and indications, supported by strategic partnerships and regulatory approvals.
Achieved Q4 2024 GAAP Net Income of $3.6 million.
Full-year 2024 Net Revenue reached $144.2 million, up 14% year-over-year.
Full-year 2024 adjusted EBITDA was $8.6 million.
ZYNRELEF Q4 2024 Net Revenue was $8.5 million, with the ZYNRELEF Vial Access Needle (VAN) launched in December 2024.
Heron Therapeutics
Heron Therapeutics
Heron Therapeutics Revenue by Segment
Revenue by Segment
CINVANTI Revenue
CapyFin.comSUSTOL Revenue
CapyFin.comZYNRELEF Revenue
CapyFin.comAPONVIE Revenue
CapyFin.com Forward Guidance
Heron Therapeutics provided full-year 2025 guidance for net revenue between $153.0 million and $163.0 million, and adjusted EBITDA between $0.0 million and $8.0 million.
Positive Outlook
- Net Revenue between $153.0 million and $163.0 million
- Adjusted EBITDA between $0.0 million and $8.0 million
- Partnership with Crosslink Network, LLC expands the promotional effort for ZYNRELEF.
- Expanded label indications for ZYNRELEF now cover an estimated 17 million annual targeted procedures.
- ZYNRELEF will continue to receive separate payment from April 1, 2025, until at least the end of 2027.